Jto

8 papers10 directions

Papers by Year

2025 1
2024 3
2023 2
2022 2

Top Research Directions

Research directions most represented by papers from this venue.

Building Empirical Null Distributions Through Permutation Testing 1
The Non-Additive Toxicity of Multi-Modal Adjunctive Therapies 1
Machine Learning for Granular Prognostic Risk Stratification 1
Transforming Continuous Biomarkers into Actionable Clinical Thresholds 1
Designing Machine Learning Models to Minimize False Negatives 1
Remodeling the Tumor Microenvironment with Combination Immunotherapy 1
Closing the Early Stage Cancer Diagnostic Gap 1
Overcoming Resistance and Toxicity in Conventional Cancer Therapies 1
Stratifying Patients for Targeted Immunotherapy Response 1
Evaluating Clinical Outcomes Using Historical Patient Cohorts 1

Top Authors

AuthorPapers
Jorge J. Nieva5
Jianhua Chen2

Papers

TitleYear
Characteristics of Short-Term Survivors With ALK or ROS1-Altered Metastatic NSCLC2025
Changing Treatment and Metastatic Disease Patterns in Patients with EGFR Mutated NSCLC: An Academic Thoracic Medical Investigator’s Consortium Registry Analysis2024
Characteristics of Long-Term Survivors With EGFR-Mutant Metastatic NSCLC2024
Improving Lung Cancer Screening Selection: The HUNT Lung Cancer Risk Model for Ever-Smokers Versus the NELSON and 2021 United States Preventive Services Task Force Criteria in the Cohort of Norway: A 2024
Biopsy Method and Needle Size on Success of Next-Generation Sequencing in NSCLC: A Brief Report2023
Response to Letter to the Editor Titled “Seize the Opportunity With Small Tissue Samples: The Tailor Teaches!”2023
Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Nonsquamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial2022
Phase 1 Study of the Selective c-MET Inhibitor, HS-10241, in Patients With Advanced Solid Tumors2022